Your browser doesn't support javascript.
loading
In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
Iovleva, Alina; McElheny, Christi L; Fowler, Erin L; Cober, Eric; Herc, Erica S; Arias, Cesar A; Hill, Carol; Baum, Keri; Fowler, Vance G; Chambers, Henry F; Greenwood-Quaintance, Kerryl E; Patel, Robin; van Duin, David; Bonomo, Robert A; Doi, Yohei.
Afiliación
  • Iovleva A; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • McElheny CL; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Fowler EL; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Cober E; Department of Infectious Diseases, Cleveland Clinic, Cleveland, Ohio, USA.
  • Herc ES; Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan, USA.
  • Arias CA; Division of Infectious Diseases, Houston Methodist Hospital, Houston, Texas, USA.
  • Hill C; Center for Infectious Diseases, Houston Methodist Research Institute, Houston, Texas, USA.
  • Baum K; Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
  • Fowler VG; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Chambers HF; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Greenwood-Quaintance KE; Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Patel R; Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
  • van Duin D; Division of Infectious Diseases, University of California San Francisco School of Medicine, San Francisco, California, USA.
  • Bonomo RA; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Doi Y; Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Antimicrob Agents Chemother ; 68(3): e0125823, 2024 Mar 06.
Article en En | MEDLINE | ID: mdl-38289078
ABSTRACT
The activity of a novel ß-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones por Acinetobacter / Acinetobacter baumannii / Compuestos de Azabiciclo Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Infecciones por Acinetobacter / Acinetobacter baumannii / Compuestos de Azabiciclo Límite: Humans Idioma: En Revista: Antimicrob Agents Chemother Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos